EGFR and non-small cell lung carcinoma: From the humble beginnings of the first-generation TKIs, exemplified by erlotinib and gefitinib in EGFR-mutant disease, to the cutting-edge third-generation agents such as osimertinib and extending the application of TKI treatment to other oncogene-driven diseases, we have witnessed a remarkable transformation in the therapeutic landscape of NSCLC [168].